Cuorips Inc. (4894) AI Stock Analysis

• Market Cap: ¥58.96B
• Dividend Yield: N/A
• Average Volume (3M): 107.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: 1772.85%
• EPS Growth: 16.16%
• Country: JP
• Employees: 59
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -30.15
• Shares Outstanding: 8,273,376
• 10 Day Avg. Volume: 98,200
• 30 Day Avg. Volume: 107,556
• PEG Ratio: 16.56
• Price to Book (P/B): 12.03
• Price to Sales (P/S): 379.55
• P/FCF Ratio: -74.48
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 49 Neutral
• Price Target: ¥7,313.00 ▲(17.38% Upside)
• Action: Reiterated Date: 03/03/26
• Date: Action: Reiterated 03/03/26

The score is primarily held back by weak financial performance driven by large losses and heavy cash burn despite strong revenue growth and a debt-free balance sheet. Technicals also lean bearish with the stock below key moving averages and negative MACD, while valuation remains constrained by negative earnings and no dividend support.

Positive Factors

Revenue Growth / Commercial Traction

Sharp, sustained top-line growth indicates the company is converting R&D and go-to-market investments into real sales and early commercial traction. Over a 2–6 month horizon this suggests expanding market acceptance and a clearer path to leverage fixed costs, improving odds of eventual scale efficiencies.

Gross Margin / Unit Economics

A roughly 52% gross margin signals healthy underlying unit economics that can support profitable operations once scale and operating leverage improve. Durable margins reduce the break-even revenue threshold and provide long-term capacity to fund R&D and sales investment without destroying product-level profitability.

Debt-Free Balance Sheet / Financial Flexibility

Zero reported debt and a sizable equity base give the company financial flexibility: no interest burden or covenant pressure and greater optionality to raise capital or invest in growth. Over months this lowers bankruptcy risk and preserves strategic choices for funding commercialization or trials.

Negative Factors

Large Operating and Net Losses

Very large recurring operating and net losses erode equity and indicate the current business model and cost base are not yet self-sustaining. Persisting deficits force continuous external funding, raise execution risk, and lengthen the timeline to profitability unless material cost or revenue inflections occur.

High Cash Burn / Negative Free Cash Flow

Deep negative operating and free cash flow show the company is consuming cash faster than it generates it, creating a tangible runway constraint. Over a multi-month horizon this increases dependency on external financing, raises dilution or refinancing risk, and limits capacity to fund growth without raising capital.

Negative Returns and Dilution Risk

A negative ROE signals that deployed capital is destroying shareholder value to date. Because operations are equity-funded, management may need to issue more shares to sustain growth, risking dilution. Persistently negative returns reduce long-term investor incentives and constrain reinsuring long-term capital.

Cuorips Inc. Business Overview & Revenue Model

Company Description

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Cuorips Inc. generates revenue through the development and commercialization of regenerative medicine products targeting cardiac diseases. The company makes money by licensing its proprietary technologies and therapies to pharmaceutical and biotechnology companies. Additionally, Cuorips Inc. may receive funding through collaborative research agreements and partnerships with healthcare institutions and academic entities. Revenue streams could also include milestone payments and royalties from successfully developed and marketed therapies. The company's earnings are significantly influenced by its ability to advance its pipeline products through clinical trials and secure regulatory approvals.

Cuorips Inc. Financial Statement Overview

Summary

Strong revenue growth and solid gross margin are outweighed by very large operating and net losses and significant negative operating/free cash flow. The debt-free, equity-supported balance sheet provides flexibility, but ongoing burn and negative returns remain key risks.

Income Statement

Revenue has scaled sharply in the latest year (2025 annual revenue up ~404% to ~¥175m), and gross margin remains solid (~52%). However, profitability is very weak: operating losses remain extremely large (EBIT about -¥590m) and net losses deepened to about -¥644m, leaving net margin highly negative. Overall, the company shows early commercial traction but still lacks a clear path to operating breakeven based on the current cost structure.

Balance Sheet

The balance sheet is conservatively levered with zero reported debt and meaningful equity (~¥5.5b) supporting a largely equity-funded profile. That said, returns remain negative (return on equity around -11.7% in 2025), indicating ongoing value dilution risk if losses persist. Overall financial flexibility looks good, but sustained losses continue to pressure long-term capital efficiency.

Cash Flow

Cash generation is weak, with operating cash flow negative and worsening in 2025 (about -¥813m), and free cash flow also deeply negative (about -¥893m), implying a high cash burn profile. Free cash flow is consistently negative relative to net income (free cash flow to net income > 1), suggesting losses are translating into real cash outflows rather than being primarily non-cash. The key strength is consistency of reporting and a lack of debt-related cash burden, but the burn rate remains the central risk.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	260.31M	175.21M	23.10M	38.28M	13.91M	220.00K
Gross Profit	119.12M	91.56M	-60.47M	-57.64M	-82.09M	-73.78M
EBITDA	-511.99M	-513.57M	-518.38M	-371.78M	-280.46M	-207.93M
Net Income	-652.25M	-644.34M	-632.18M	-452.08M	-375.34M	-307.83M
Balance Sheet
Total Assets	5.75B	5.74B	6.18B	3.59B	4.04B	4.36B
Cash, Cash Equivalents and Short-Term Investments	4.85B	4.79B	5.58B	2.94B	3.34B	3.54B
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	324.59M	211.91M	200.96M	133.79M	149.36M	141.95M
Stockholders Equity	5.42B	5.53B	5.98B	3.45B	3.90B	4.22B
Cash Flow
Free Cash Flow	0.00	-892.81M	-474.83M	-412.18M	-249.45M	-950.97M
Operating Cash Flow	0.00	-812.62M	-451.06M	-401.61M	-220.76M	-282.80M
Investing Cash Flow	0.00	-117.99M	-33.50M	-8.97M	-28.44M	-670.21M
Financing Cash Flow	0.00	143.11M	3.12B	10.69M	48.54M	3.77B

Cuorips Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6230.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Positive. The current price of 6230 is below the 20-day moving average (MA) of 7220.50, below the 50-day MA of 7998.00, and below the 200-day MA of 6835.35, indicating a neutral trend. The MACD of -371.26 indicates Positive momentum. The RSI at 45.61 is Neutral, neither overbought nor oversold. The STOCH value of 44.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4894.

Cuorips Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4978	56 Neutral	¥16.02B	120.78	―	―	1.24%	-33.41%
7774	54 Neutral	¥24.81B	-34.16	―	―	-5.65%	-469.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4593	50 Neutral	¥53.60B	-13.30	―	―	-82.33%	47.73%
4894	49 Neutral	¥58.96B	-49.98	―	―	1772.85%	16.16%
7776	49 Neutral	¥12.00B	-8.14	―	―	-42.49%	-2.37%
4599	43 Neutral	¥18.55B	-11.30	―	―	―	11.34%